This was unlikely to be the result of improved neoantigen-specific CD8+ T cell responses before tumor challenge, as we observed fewer tetramer-positive and cytokine-producing CD8+ T cells in blood and spleen. The gene discussed is CD8A; the disease is neoplasm.